AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
SciSparc Ltd.
Video analysis: SPRC
All videosNo video analysis for this stock yet. Request one from our team.
News: SPRC
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
This strategic engagement is designed to strengthen NeuroThera's U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public ‑ health importance of advancing new treatment options for adult Tourette Syndrome TEL AVIV, Israel – TheNewswire - September 2, 2026 - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced that it is pursuing U.S. Food and Drug Administration (“FDA”) Orphan Drug Designation covering SCI-110, its drug candidate for the treatment adults with Tourette Syndrome (“TS”), a rare condition that may qualify for Orphan Drug Designation.
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
This strategic engagement is designed to strengthen NeuroThera's U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public ‑ health importance of advancing new treatment options for adult Tourette Syndrome TEL AVIV, Israel – TheNewswire - September 2, 2026 - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced that it is pursuing U.S. Food and Drug Administration (“FDA”) Orphan Drug Designation covering SCI-110, its drug candidate for the treatment adults with Tourette Syndrome (“TS”), a rare condition that may qualify for Orphan Drug Designation.
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, continued advancement in participant enrollment for the clinical trial assessing NeuroThera's innovative SCI-210 treatment for symptoms associated with autism spectrum disorder (“ASD”).
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
Toronto, Ontario, August 31, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced continued advancement in participant enrollment for its clinical trial assessing its innovative SCI-210 treatment for symptoms associated with autism spectrum disorder (“ ASD ”). The clinical trial, conducted at Soroka Medical Center in Israel, is a double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of SCI-210 in children diagnosed with ASD. To date, 26 children have been enrolled, marking strong progress toward the planned total of 60 children between the ages of five and 18, each of whom will receive treatment over a 20-week period.
Neurothera Labs Inc. Announces Share Consolidation
Toronto, Ontario – August 28, 2026 – – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that, in accordance with special resolution of shareholders passed on January 8, 2026 (the “ Consolidation Resolution ”), the Company will be implementing a consolidation (the “ Consolidation ”) of the outstanding common shares in the capital of the Company (the “ Common Shares ”) on the basis of one new Common Share (each, a “ Post-Consolidation Share ”) for every fourteen (14) currently outstanding Common Shares (the " Consolidation Ratio "). The Company believes that the increase to the trading price of the Common Shares from effecting the consolidation could potentially and principally broaden the pool of investors that may consider investing or be able to invest in the Company as well as enable the Company to satisfy certain minimum trading price requirements of U.S. and other stock exchanges for a potential listing of the Common Shares.
NeuroThera Labs Engages Dr. Reuter Investor Relations
Toronto, Ontario – August 27, 2026 – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has engaged Dr. Reuter Investor Relations (" Dr. Reuter ") to provide investor awareness and communications services across Germany and the broader European capital markets, effective September 1, 2026. Dr. Reuter is a recognized European investor relations and financial communications firm with an established network of institutional investors, retail shareholders, and financial media throughout the DACH region and the European Union. The engagement is intended to enhance the Company's visibility among European investors, support market education regarding its clinical research strategy, and strengthen shareholder communications. Dr. Reuter's business address is Tower 185, Friedrich-Ebert-Anlage 35-37, 60327 Frankfurt, Germany, and the firm may be contacted at e.reuter@dr-reuter.eu .
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
The addition of leading AI researcher further strengthens SciSparc's scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical development considerations for psychedelic drugs, including MDMA
